PALO ALTO, Calif., July 29 /PRNewswire/ -- Nfocus Neuromedical Inc. announced today at the 6th Annual Meeting of the Society of NeuroInterventional Surgery (www.snisonline.org) that Nfocus has earned a European CE Mark approval for its novel guiding catheter, the Echo(TM) Distal Access Catheter.
"The Echo's unique construction gives it the ability to enable endovascular procedures in very far-reaching vessel locations -- yet provide a stable platform for placing today's most advanced interventional devices," noted President and CEO Martin S. Dieck.
"The European CE Mark approval gives Nfocus the ability to enter the top end of the interventional guiding catheter market with our new Echo catheter. Endovascular surgeons and interventional neuroradiologists will appreciate the extreme suppleness of the distal end and the exceptional support of the proximal section -- both produced by the key uni-body construction."
The Echo(TM) Distal Access Catheter has been cleared in Europe to provide support and vessel access in peripheral, coronary and neurovascular interventional and diagnostic procedures. In today's advanced and complex endovascular procedures, a high-quality guiding catheter is required to allow operative devices or implants to reach the target vessel. It is critical for the guiding catheter to be atraumatic and flexible within the distant and smaller target vessel -- yet provide stable and firm support in the larger vessels where the device enters the body.
"Nfocus recognized a key market opportunity and has applied its unique design and development talents to produce the Echo," continued Mr. Dieck. "Echo will help enable many advanced endovascular procedures."
About Nfocus Neuromedical Inc.
Nfocus is positioning itself to be the world-wide leader in the development of next-generation endovascular neurosurgery solutions (surgery through less-invasive catheter devices) . Backed by premier venture investors, the Company is developing revolutionary systems to treat neurovascular disease, including brain aneurysms, that are simple, safe, cost-effective and curative.
Nfocus was incubated at In-Cube Labs and is backed by Oxford Bioscience Partners, Technology Partners and DFJ-ePlanet Ventures.
To learn more about the Nfocus Neuromedical development programs focused on providing faster, simpler and more permanent treatment of vascular diseases of the brain and spine, please visit the new Nfocus website at: www.nfocusneuro.com.
|SOURCE Nfocus Neuromedical Inc.|
Copyright©2009 PR Newswire.
All rights reserved